Healthcare provider profile · identity verified

Roger G Peck, MD

Internal Medicine · MANHATTAN, KS · NPI 1972570331

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	249	61
Levothyroxine Sodium	Levothyroxine Sodium	189	44
Rosuvastatin Calcium	Rosuvastatin Calcium	161	41
Amlodipine Besylate	Amlodipine Besylate	160	42
Losartan Potassium	Losartan Potassium	142	36
Omeprazole	Omeprazole	123	32
Pravastatin Sodium	Pravastatin Sodium	116	27
Lisinopril	Lisinopril	115	37
Tamsulosin Hcl	Tamsulosin Hcl	111	30
Metformin Hcl Er	Metformin Hcl	108	26
Hydrochlorothiazide	Hydrochlorothiazide	95	25
Metoprolol Succinate	Metoprolol Succinate	91	26
Metformin Hcl	Metformin Hcl	90	27
Gabapentin	Gabapentin	88	25
Meloxicam	Meloxicam	84	21
Pantoprazole Sodium	Pantoprazole Sodium	77	21
Allopurinol	Allopurinol	72	20
Furosemide	Furosemide	69	19
Clopidogrel	Clopidogrel Bisulfate	64	19
Warfarin Sodium	Warfarin Sodium	63	11
Montelukast Sodium	Montelukast Sodium	60	13
Temazepam	Temazepam	59	suppressed
Farxiga	Dapagliflozin Propanediol	57	14
Trazodone Hcl	Trazodone Hcl	55	14
Zolpidem Tartrate	Zolpidem Tartrate	54	suppressed
Carvedilol	Carvedilol	53	14
Ozempic	Semaglutide	50	suppressed
Tizanidine Hcl	Tizanidine Hcl	50	suppressed
Simvastatin	Simvastatin	49	13
Potassium Chloride	Potassium Chloride	48	11
Tramadol Hcl	Tramadol Hcl	45	16
Glipizide	Glipizide	44	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	42	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	41	suppressed
Donepezil Hcl	Donepezil Hcl	40	11
Eliquis	Apixaban	38	suppressed
Spironolactone	Spironolactone	38	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	37	suppressed
Indapamide	Indapamide	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Telmisartan	Telmisartan	34	11
Metoprolol Tartrate	Metoprolol Tartrate	33	suppressed
Sertraline Hcl	Sertraline Hcl	32	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	32	suppressed
Chlorthalidone	Chlorthalidone	31	suppressed
Jardiance	Empagliflozin	31	suppressed
Tresiba Flextouch U-100	Insulin Degludec	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Memantine Hcl	Memantine Hcl	29	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	28	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Fluticasone Propionate	Fluticasone Propionate	28	11
Testosterone Cypionate	Testosterone Cypionate	28	suppressed
Alprazolam	Alprazolam	27	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	suppressed
Pregabalin	Pregabalin	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Minoxidil	Minoxidil	25	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Famotidine	Famotidine	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Methotrexate	Methotrexate Sodium	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	15
Glipizide Er	Glipizide	19	suppressed
Irbesartan	Irbesartan	19	suppressed
Labetalol Hcl	Labetalol Hcl	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Valsartan	Valsartan	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Celecoxib	Celecoxib	17	suppressed
Topiramate	Topiramate	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	14
Finasteride	Finasteride	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Prednisone	Prednisone	14	suppressed
Tradjenta	Linagliptin	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Sotalol	Sotalol Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Ramipril	Ramipril	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Atenolol	Atenolol	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Estradiol	Estradiol	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error